Artiva Biotherapeutics, Inc. Common Stock (ARTV)
9.97
(-9.69%)
9.97
(-9.69%)
| Breakdown | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|
| Revenue | 33.49 Million | 4.93 Million | 2 Million | - |
| Cost of Revenue | - | - | - | - |
| Gross Profit | 33.49 Million | 4.93 Million | 2 Million | - |
| Operating Expenses | 64.16 Million | 64.76 Million | 55.27 Million | 18.27 Million |
| Selling, General and Administrative Expenses | 13.91 Million | 20.77 Million | 12.86 Million | 4.42 Million |
| Research and Development Expenses | 50.25 Million | 43.98 Million | 42.41 Million | 13.84 Million |
| Other Expenses | - | 200 Thousand | -18.55 Million | 477 Thousand |
| Cost and Expenses | 64.16 Million | 64.76 Million | 55.27 Million | 18.27 Million |
| Operating Income | -30.67 Million | -59.82 Million | -53.27 Million | -18.27 Million |
| Interest Expense | - | - | - | 199 Thousand |
| Income Tax Expense | 72 Thousand | 53 Thousand | -18.55 Million | 676 Thousand |
| Earnings before Tax | -27.62 Million | -58.33 Million | -71.82 Million | -17.99 Million |
| Net Income | -27.69 Million | -58.38 Million | -71.82 Million | -17.99 Million |
| Earnings Per Share Basic | -2.96 | -3.32 | -4.08 | -1.02 |
| Earnings Per Share Diluted | -2.96 | -3.32 | -4.08 | -1.02 |
| Weighted Average Shares Outstanding | 9.35 Million | 17.58 Million | 17.58 Million | 17.58 Million |
| Weighted Average Shares Outstanding (Diluted) | 9.35 Million | 17.58 Million | 17.58 Million | 17.58 Million |
| Gross Margin | 1.00 | 1.00 | 1.00 | - |
| EBIT Margin | -0.85 | -11.90 | -35.75 | - |
| Profit Margin | -0.83 | -11.84 | -35.88 | - |
| EBITDA | -28.4 Million | -58.67 Million | -71.57 Million | -17.71 Million |
| Earnings Before Tax Margin | -0.92 | -12.13 | -26.61 | - |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q2 | 2023 Q1 | 2022 FY |
|---|---|---|---|---|---|---|
| Revenue | - | 251 Thousand | 33.49 Million | - | 989 Thousand | 4.93 Million |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | 251 Thousand | 33.49 Million | - | 989 Thousand | 4.93 Million |
| Operating Expenses | 16.19 Million | 14.74 Million | 64.16 Million | 15.32 Million | 18.67 Million | 64.76 Million |
| Selling, General and Administrative Expenses | 3.85 Million | 3.58 Million | - | 4.05 Million | 3.9 Million | - |
| Research and Development Expenses | 12.33 Million | 11.15 Million | - | 11.26 Million | 14.77 Million | - |
| Other Expenses | -23 Thousand | 147 Thousand | -195 Thousand | -31 Thousand | -53 Thousand | 200 Thousand |
| Cost and Expenses | 16.19 Million | 14.74 Million | 64.16 Million | 15.32 Million | 18.67 Million | 64.76 Million |
| Operating Income | -16.19 Million | -14.49 Million | -30.67 Million | -11.82 Million | -17.68 Million | -59.82 Million |
| Interest Expense | - | - | - | - | - | - |
| Income Tax Expense | -1.67 Million | -382 Thousand | 72 Thousand | 509 Thousand | -1.02 Million | 53 Thousand |
| Earnings before Tax | -14.53 Million | -13.96 Million | -27.62 Million | -15.86 Million | -16.71 Million | -58.33 Million |
| Net Income | -17 Million | -13.96 Million | -27.69 Million | -15.86 Million | -16.71 Million | -58.38 Million |
| Earnings Per Share Basic | -0.97 | -0.79 | - | -0.90 | -0.95 | - |
| Earnings Per Share Diluted | -0.97 | -0.79 | - | -0.90 | -0.95 | - |
| Weighted Average Shares Outstanding | 17.58 Million | 17.58 Million | 17.58 Million | 17.58 Million | 17.58 Million | 17.58 Million |
| Weighted Average Shares Outstanding (Diluted) | 17.58 Million | 17.58 Million | 17.58 Million | 17.58 Million | 17.58 Million | 17.58 Million |
| Gross Margin | - | 1.00 | 1.00 | - | 1.00 | 1.00 |
| EBIT Margin | - | -54.33 | - | - | -17.30 | - |
| Profit Margin | - | -55.63 | -0.83 | - | -16.90 | -11.84 |
| EBITDA | -17.93 Million | -13.63 Million | - | -14.78 Million | -17.11 Million | - |
| Earnings Before Tax Margin | - | -57.74 | -0.92 | - | -17.88 | -12.13 |
SGP
CGIP
9668
NVX
9253
5JK